Chargement en cours...
Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors—What Some May Have Forgotten or Would Rather Forget?
Hydroxamate-based histone deacetylase inhibitors (HDACIs) have been approved as therapeutic agents by the US Food and Drug Administration for use in oncology applications. While the potential utility of such HDACIs in other areas of medicinal chemistry is tremendous, there are significant concerns t...
Enregistré dans:
| Publié dans: | ChemMedChem |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4765907/ https://ncbi.nlm.nih.gov/pubmed/26603496 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cmdc.201500486 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|